0001209191-17-008912.txt : 20170208 0001209191-17-008912.hdr.sgml : 20170208 20170208194045 ACCESSION NUMBER: 0001209191-17-008912 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170206 FILED AS OF DATE: 20170208 DATE AS OF CHANGE: 20170208 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: OBrien Christopher Flint CENTRAL INDEX KEY: 0001343124 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 17584058 MAIL ADDRESS: STREET 1: 12790 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-02-06 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001343124 OBrien Christopher Flint 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Medical Officer Common Stock 2017-02-06 4 S 0 1206 43.17 D 37038 D Stock Option 43.24 2017-02-06 4 A 0 76800 0.00 A 2027-02-06 Common Stock 76800 76800 D Restricted Stock Option 2017-02-06 4 A 0 10600 0.00 A Common Stock 10600 10600 D Sale of 1206 shares of common stock issued upon vesting of 3200 restricted stock units to cover withholding taxes with the balance of the shares (1994) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $42.91 to $43.46. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2017 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Each Restricted Stock Unit represents a contingent right to receive one share of the Neurocrine Common Stock. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2018, February 6, 2019, February 6, 2020, and February 6, 2021. /s/ Darin Lippoldt, Attorney-In-Fact 2017-02-08